Verinder S Sidhu, Thu-Lan Kelly, Nicole Pratt, Stephen E Graves, Rachelle Buchbinder, Sam Adie, Kara Cashman, Ilana N Ackerman, Durga Bastiras, Roger Brighton, Alexander W R Burns, Beng Hock Chong, Ornella Clavisi, Maggie Cripps, Mark Dekkers, Richard de Steiger, Michael Dixon, Andrew Ellis, Elizabeth C Griffith, David Hale, Amber Hansen, Anthony Harris, Raphael Hau, Mark Horsley, Dugal James, Omar Khorshid, Leonard Kuo, Peter L Lewis, David Lieu, Michelle Lorimer, Samuel J MacDessi, Peter McCombe, Catherine McDougall, Jonathan Mulford, Justine Maree Naylor, Richard S Page, John Radovanovic, Michael Solomon, Rami Sorial, Peter Summersell, Phong Tran, William L Walter, Steve Webb, Chris Wilson, David Wysocki, Ian A Harris
IMPORTANCE: Ischemic heart disease remains the leading cause of mortality following hip and knee arthroplasty. Due to its antiplatelet and cardioprotective properties, aspirin has been proposed as an agent that could reduce mortality when used as venous thromboembolism (VTE) prophylaxis following these procedures. OBJECTIVE: To compare aspirin with enoxaparin in reducing 90-day mortality for patients undergoing hip or knee arthroplasty procedures. DESIGN, SETTING, AND PARTICIPANTS: This study was a planned secondary analysis of the CRISTAL cluster randomized, crossover, registry-nested trial performed across 31 participating hospitals in Australia between April 20, 2019, and December 18, 2020...
June 1, 2023: JAMA Network Open